PMC:5711939 / 24259-25567 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/5711939","sourcedb":"PMC","sourceid":"5711939","source_url":"https://www.ncbi.nlm.nih.gov/pmc/5711939","text":"Lynronne-1, Lynronne-2 and Lynronne-3 are efficacious against clinically important drug-resistant pathogens in in vitro models of infection. In addition, Lynronne-1 decreased bacterial counts in MRSA wound infections using a murine model, similar to commercially used mupirocin ointment, suggesting that it could be used topically in the treatment of MDR bacterial infections. Lynronne 1, 2 and 3 displayed low haemolytic activity against blood cells and negligible cytotoxicity against mammalian cells. Results presented here suggest that loss of cell viability after exposure to Lynronne-1, Lynronne-2 and Lynronne-3 among many factors is due to membrane permeabilization, which contributes to membrane disruption and leakage of cell content. In addition to their broad antibacterial spectrum, selectivity and rapid killing of bacterial cells, Lynronne-1, Lynronne-2 and Lynronne-3 also showed a low tendency to select for resistance in the bacteria strains tested. The antimicrobial compounds discovered here are novel and demonstrate potent activity against clinically relevant human pathogens, rendering them as potential therapeutics. The identification of these novel AMPs support the hypothesis that the rumen is a promising resource for the discovery of novel antimicrobials with clinical relevance.","tracks":[]}